Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Opgen Inc (OPGN)

Opgen Inc (OPGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,973
  • Shares Outstanding, K 882
  • Annual Sales, $ 2,950 K
  • Annual Income, $ -13,370 K
  • 60-Month Beta 0.78
  • Price/Sales 1.95
  • Price/Cash Flow N/A
  • Price/Book 3.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -2.60
  • Number of Estimates 1
  • High Estimate -2.60
  • Low Estimate -2.60
  • Prior Year -10.60
  • Growth Rate Est. (year over year) +75.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.01 +19.55%
on 10/14/19
8.46 -15.07%
on 09/16/19
-0.82 (-10.19%)
since 09/13/19
3-Month
4.20 +70.91%
on 08/08/19
12.80 -43.87%
on 09/04/19
-0.02 (-0.21%)
since 07/12/19
52-Week
4.20 +70.91%
on 08/08/19
40.60 -82.30%
on 01/09/19
-31.82 (-81.58%)
since 10/12/18

Most Recent Stories

More News
OpGen Presents Preliminary Acuitas(R) AMR Gene Panel Data for Detecting Urinary Tract Infections

OpGen, Inc. (Nasdaq: OPGN) today announced the presentation of preliminary data at IDWeek 2019 for the Company's Acuitas AMR Gene Panel and Acuitas Lighthouse Software for the detection of urinary tract...

OPGN : 7.18 (+6.13%)
OpGen to Present on Guiding Precision Antibiotic Therapy with Rapid Genomics and Informatics at IDWeek 2019

OpGen, Inc. (Nasdaq: OPGN) announced today that data from its Acuitas AMR Gene Panel and Acuitas Lighthouse Software will be presented during IDWeek 2019, taking place October 2-6 in Washington, D.C. at...

OPGN : 7.18 (+6.13%)
OpGen Provides update on Curetis Group's R&D Collaboration

OpGen, Inc. (Nasdaq: OPGN) reported an update on the business of Curetis GmbH, the other party to the planned business combination with OpGen. On September 16, 2019, Curetis, N.V. announced that its wholly-owned...

OPGN : 7.18 (+6.13%)
Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses

-- Combined company to be headquartered in Gaithersburg, MD, USA

OPGN : 7.18 (+6.13%)
CURE : 49.97 (+0.04%)
OpGen Reports Second Quarter 2019 Financial Results and Provides Business Update

Revenue up 28% Quarter-over-Quarter

OPGN : 7.18 (+6.13%)
OpGen Announces Date of Second Quarter 2019 Financial Results Conference Call

OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its second quarter 2019 financial results after the close of the U.S. financial markets on Wednesday, August 7, 2019. OpGen's management...

OPGN : 7.18 (+6.13%)
OpGen's Acuitas(R) AMR Gene Panel Shows Potential for Reducing Total Time to Targeted Therapy

Collaborator data demonstrating OpGen's rapid prediction of antibiotic resistance and detection of uropathogens presented at ASM Microbe 2019

OPGN : 7.18 (+6.13%)
OpGen, Inc. (OPGN) Reports Q1 Loss, Misses Revenue Estimates

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -24.24% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

OPGN : 7.18 (+6.13%)
OpGen Completes Initial FDA 510(k) Submission for its Acuitas(R) AMR Gene Panel Test to Identify Presence of Antibiotic Resistance

OpGen, Inc. (Nasdaq: OPGN) announced today that it has filed its 510(k) submission with the U.S. Food and Drug Administration (FDA) for clearance for its Acuitas AMR Gene Panel test for the detection of...

OPGN : 7.18 (+6.13%)
Will OpGen, Inc. (OPGN) Report Negative Q1 Earnings? What You Should Know

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OPGN : 7.18 (+6.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade OPGN with:

Business Summary

OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland.

See More

Key Turning Points

2nd Resistance Point 9.49
1st Resistance Point 8.34
Last Price 7.18
1st Support Level 6.02
2nd Support Level 4.86

See More

52-Week High 40.60
Fibonacci 61.8% 26.70
Fibonacci 50% 22.40
Fibonacci 38.2% 18.11
Last Price 7.18
52-Week Low 4.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar